{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:55Z","timestamp":1791912475306,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-03014-5","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T05:11:08Z","timestamp":1730178668000},"page":"4628-4647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risk\u2013Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis"],"prefix":"10.1007","volume":"41","author":[{"given":"A. Gordon","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"3014_CR1","doi-asserted-by":"crossref","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Investig. 2024;134(12).","DOI":"10.1172\/JCI179742"},{"key":"3014_CR2","doi-asserted-by":"crossref","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11).","DOI":"10.3390\/jcm10112235"},{"key":"3014_CR3","unstructured":"Myasthenia Gravis Foundation of America (MGFA). Clinical overview of MG 2015. https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG. Accessed 14 May 2023."},{"issue":"1","key":"3014_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho S-M, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8\u201319.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3014_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"key":"3014_CR6","doi-asserted-by":"crossref","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6).","DOI":"10.3390\/jcm11061597"},{"issue":"3","key":"3014_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JND-170294","volume":"5","author":"A Behin","year":"2018","unstructured":"Behin A, Le Panse R. New pathways and therapeutic targets in autoimmune myasthenia gravis. J Neuromuscul Dis. 2018;5(3):265\u201377.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"3014_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","volume":"33","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545\u201352.","journal-title":"Curr Opin Neurol"},{"key":"3014_CR9","unstructured":"Tice JA, Touchette DR, Nikitin D, Campbell JD, Lien P-W, Moradi A, et al. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value: Institute for Clinical and Economic Review; 2021. https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf. Accessed 14 May 2023."},{"key":"3014_CR10","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: SOLIRIS (eculizumab) injection, for intravenous use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf. Accessed May 15, 2023."},{"issue":"12","key":"3014_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3014_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"3014_CR13","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: VYVGART (efgartigimod alfa-fcab), for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf. Accessed 15 May 2023."},{"key":"3014_CR14","doi-asserted-by":"crossref","unstructured":"Howard JF, Vu T, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the Phase 3 CHAMPION MG open-label extension (S25.005). Neurology. 2022;98(18_suppl):853.","DOI":"10.1212\/WNL.98.18_supplement.853"},{"key":"3014_CR15","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf. Accessed 15 May 2023."},{"issue":"5","key":"3014_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394.","journal-title":"Lancet Neurol"},{"key":"3014_CR17","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: RYSTIGGO (rozanolixizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf. Accessed 21 Mar 2024."},{"issue":"5","key":"3014_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"key":"3014_CR19","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ZILBRYSQ (zilucoplan). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf. Accessed 21 Mar 2024."},{"key":"3014_CR20","unstructured":"Li Y, JF Howard, Li G. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in patients with generalized myasthenia gravis: Interim results of the ADAPT-SC+ study. American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Meeting; November 1\u20134, 2023; Phoenix, AZ."},{"issue":"12","key":"3014_CR21","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Euro J Neurol. 2023;30(12):3854\u201367.","journal-title":"Euro J Neurol"},{"key":"3014_CR22","doi-asserted-by":"crossref","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","DOI":"10.1212\/WNL.52.7.1487"},{"key":"3014_CR23","doi-asserted-by":"crossref","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"issue":"5","key":"3014_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311.","journal-title":"Int J Clin Pract"},{"key":"3014_CR25","unstructured":"IBM Watson Health. MicroMedex RED BOOK 2024. https:\/\/www.ibm.com\/products\/micromedex-red-book."},{"key":"3014_CR26","unstructured":"Centers for Medicare & Medicaid Services (CMS). 2024 Physician Fee Schedule. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched."},{"key":"3014_CR27","unstructured":"Qi C, Brauer E, Gelinas D, Goyal A, Bergin C, editors. Real-world usage patterns of Vyvgart in adults with generalized myasthenia gravis in the United States. In: 45th annual Carrell-Krusen neuromuscular symposium; 2023 February 23\u201324, 2023; Dallas, TX, USA."},{"issue":"1","key":"3014_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/CND.0000000000000301","volume":"22","author":"L Harris","year":"2020","unstructured":"Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the United States. J Clin Neuromuscul Dis. 2020;22(1):11\u201321.","journal-title":"J Clin Neuromuscul Dis"},{"key":"3014_CR29","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/pdf\/Bookshelf_NBK310366.pdf. Accessed 16 Sept 2024."},{"key":"3014_CR30","unstructured":"Member State Coordination Group on HTA (HTACG). Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons 2024. https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf. Accessed 16 Sept 2024."},{"issue":"3","key":"3014_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JND-150082","volume":"2","author":"C Barnett","year":"2015","unstructured":"Barnett C, Merkies IS, Katzberg H, Bril V. Psychometric properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. J Neuromuscul Dis. 2015;2(3):301\u201311.","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"3014_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S1474-4422(23)00364-2","volume":"22","author":"HF Li","year":"2023","unstructured":"Li HF, Hu SM, Yin J, Yang H. Score fluctuation might be associated with a higher placebo rate in the RAISE trial. Lancet Neurol. 2023;22(11):982.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3014_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139.","journal-title":"Muscle Nerve"},{"key":"3014_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","volume":"12","author":"G Phillips","year":"2021","unstructured":"Phillips G, Abreu C, Goyal A, Li Y, Whangbo A, Gelinas D, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021;12: 809999.","journal-title":"Front Neurol"},{"issue":"7","key":"3014_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"18","key":"3014_CR36","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72(18):1548\u201354.","journal-title":"Neurology"},{"issue":"6","key":"3014_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68(6):797\u2013805.","journal-title":"Ann Neurol"},{"issue":"6","key":"3014_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mus.25624","volume":"56","author":"JO Omorodion","year":"2017","unstructured":"Omorodion JO, Pines JM, Kaminski HJ. Inpatient cost analysis for treatment of myasthenia gravis. Muscle Nerve. 2017;56(6):1114\u20138.","journal-title":"Muscle Nerve"},{"issue":"6","key":"3014_CR39","first-page":"517","volume":"30","author":"P-W Lien","year":"2024","unstructured":"Lien P-W, Joshi M, Tice JA, Agboola F, Nikitin D, Withanawasam V, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti\u2013acetylcholine receptor antibody\u2013positive generalized myasthenia gravis. J Manag Care Spec Pharm. 2024;30(6):517\u201327.","journal-title":"J Manag Care Spec Pharm"},{"key":"3014_CR40","doi-asserted-by":"crossref","unstructured":"Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8).","DOI":"10.3390\/jcm11082189"},{"issue":"4","key":"3014_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mus.28063","volume":"69","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, Barlow S, Chatterton E, Thomas O, et al. The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve. 2024;69(4):428\u201339.","journal-title":"Muscle Nerve"},{"key":"3014_CR42","unstructured":"Wolfe GI, Sacc\u00e0 F, Phillips G, Barnett-Tapia C, Qi C, Yang H, et al. Network meta-analysis of treatment options in generalized myasthenia gravis: impact on health-related quality of life outcome. In: American association of neuromuscular & electrodiagnostic medicine annual meeting; November 1, 2023; Phoenix, AZ."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03014-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03014-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T03:12:44Z","timestamp":1731121964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03014-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3014"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03014-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gordon Smith received consulting fees from Abalone, Alexion, Argenx, Disarm Therapeutics, Eidos, Lexicon, and Sangamo. Gil Wolfe received consulting fee from Grifols, Alexion, Argenx, Takeda, BPL, UCB, Cartesian, and Janssen, research support from ArgenX, Ra\/UCB, Immunovant, Roche, Alexion, Sanofi,\u00a0NINDS\/NIH, MGFA, and public speaking honoraria from Grifols, Alexion, UCB. Ali A. Habib received research support from Alexion\/Astra Zeneca, Argenx, UCB, Immunovant, Regeneron, CabalettaBio, VielaBio, Pfizer, and Genentech, as well as honoraria from UCB, Argenx, Alexion, Immunovant, and Regeneron. Cynthia Qi, Deborah Gelinas, Edward Brauer, and Glenn Phillips are employees of Argenx. Hongbo Yang, Mandy Du, and Xin Chen are employees of Analysis Group Inc., which received consulting fees from Argenx to conduct this study. Francesco Sacc\u00e0 received public speaking honoraria from Alexion, argenx, Biogen, Genpharm, Medpharma Madison Pharma, Zai Lab; he also received compensation for Advisory boards or consultation fees from Alexion, argenx, Biogen, Dianthus, Lexeo Therapeutics, Novartis, Reata, Sandoz; he is PI in clinical trials for Alexion, argenx, Immunovant, Lediant, Novartis, Prilenia, Remgen, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used anonymized, previously collected, or publicly published data; thus, no ethical review was required. All the original trials included in this study received institutional review board approval and patient consent. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}